Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Brown

Cardiovascular Disease Walnut Creek, CA Medical Doctor

NPI 1093719056 CMS profile 139686

1450 Treat Blvd, Suite 220B, Walnut Creek, CA 94597

Open in the dashboard

General payments

$7,922

371 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Brown of Walnut Creek, CA is reported in the CMS Open Payments database as having received $7,922 across 371 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $757 33
2024 General $990 44
2023 General $1,737 71
2022 General $1,593 73
2021 General $1,118 54
2020 General $945 47
2019 General $782 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Brown
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Michael Brown were reported at $757. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Michael Brown Cardiovascular Disease median Middle half National median
2019 $782 $450 $127–$1,392 $163
2020 $945 $242 $77–$751 $114
2021 $1,118 $335 $101–$1,037 $132
2022 $1,593 $395 $121–$1,211 $149
2023 $1,737 $443 $136–$1,283 $160
2024 $990 $450 $136–$1,323 $164
2025 $757 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biotronik Inc. $1,501 62 payments
  2. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $649 24 payments
  3. Amarin Pharma Inc. $566 32 payments
  4. Abbott Laboratories $412 18 payments
  5. Novartis Pharmaceuticals Corporation $407 23 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $390 16 payments
  7. E.R. Squibb & Sons, L.L.C. $360 17 payments
  8. Amgen Inc. $349 19 payments
  9. Atricure, Inc. $341 19 payments
  10. Impulse Dynamics (USA) Inc. $340 8 payments
  11. Other $2,607 133 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,749 356 payments
  2. Education $173 15 payments
Products named General payments · program years 2019–2025
  1. LifeVest $649 24 payments
  2. Solia $582 24 payments
  3. Vascepa $566 32 payments
  4. BioMonitor $558 26 payments
  5. Rivacor $435 21 payments
  6. Edora $435 21 payments
  7. Acticor $435 21 payments
  8. Repatha $331 18 payments
  9. JARDIANCE $299 11 payments
  10. ATRICLIP LAA EXCLUSION SYSTEM $299 17 payments
  11. Other $5,529 265 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 95 drugs

Part D claims

6,829

Median for Cardiology: 2,533

Drug cost

$1,742,666

Median for Cardiology: $485,213

Branded share of claims

30.8%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 445 $637,418
Xarelto Rivaroxaban Brand 216 $266,334
Entresto Sacubitril/Valsartan Brand 122 $147,917
Jardiance Empagliflozin Brand 113 $143,839
Multaq Dronedarone Hcl Brand 61 $103,597
Repatha Sureclick Evolocumab Brand 74 $82,167
Farxiga Dapagliflozin Propanediol Brand 60 $65,805
Repatha Pushtronex Evolocumab Brand 27 $28,641
Praluent Pen Alirocumab Brand 25 $28,437
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 31 $25,241

The 10 drugs with the highest cost, of 95 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$450,213

Of which drugs: $23,911

Medicare patients

1,849

Average age 79

Services billed

8,856

1,009 women, 840 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Atrial fibrillation 40%
Ischemic heart disease 39%
Chronic kidney disease 35%
Heart failure 31%
Diabetes 29%
Depression 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 111 444 $2,367

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $91
$91 113 —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $69
$69 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $61
$61 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $52
$52 — —
AMVUTTRA
  • Alnylam Pharmaceuticals Inc. $32
$32 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

371 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record